{"doi":"10.3390/molecules29030564","title":"A High-Throughput NMR Method for Lipoprotein-X Quantification","abstract":"Lipoprotein X (LP-X) is an abnormal cholesterol-rich lipoprotein particle that accumulates in patients with cholestatic liver disease and familial lecithin–cholesterol acyltransferase deficiency (FLD). Because there are no high-throughput diagnostic tests for its detection, a proton nuclear magnetic resonance (NMR) spectroscopy-based method was developed for use on a clinical NMR analyzer commonly used for the quantification of lipoproteins and other cardiovascular biomarkers. The LP-X assay was linear from 89 to 1615 mg/dL (cholesterol units) and had a functional sensitivity of 44 mg/dL. The intra-assay coefficient of variation (CV) varied between 1.8 and 11.8%, depending on the value of LP-X, whereas the inter-assay CV varied between 1.5 and 15.4%. The assay showed no interference with bilirubin levels up to 317 mg/dL and was also unaffected by hemolysis for hemoglobin values up to 216 mg/dL. Samples were stable when stored for up to 6 days at 4 °C but were not stable when frozen. In a large general population cohort (n = 277,000), LP-X was detected in only 50 subjects. The majority of LP-X positive cases had liver disease (64%), and in seven cases, had genetic FLD (14%). In summary, we describe a new NMR-based assay for LP-X, which can be readily implemented for routine clinical laboratory testing.","journal":"Molecules","year":2024,"id":467143,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":3,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9566,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":484346,"name":"Irina Shalaurova","orcid":"0000-0003-0191-0383","position":1,"is_corresponding":false},{"id":485518,"name":"Steven P. Matyus","orcid":null,"position":2,"is_corresponding":false},{"id":311168,"name":"Lita A. Freeman","orcid":"0000-0002-6668-1916","position":3,"is_corresponding":false},{"id":586889,"name":"Edward B. Neufeld","orcid":"0000-0002-1248-6613","position":4,"is_corresponding":false},{"id":461866,"name":"Maureen Sampson","orcid":"0000-0003-0885-250X","position":5,"is_corresponding":false},{"id":1239341,"name":"Rafael Zubirán","orcid":"0000-0003-4274-3585","position":6,"is_corresponding":false},{"id":292985,"name":"Anna Wolska","orcid":"0000-0001-9479-0741","position":7,"is_corresponding":false},{"id":257517,"name":"Alan T. Remaley","orcid":"0000-0001-5839-7280","position":8,"is_corresponding":false},{"id":293938,"name":"James D. Otvos","orcid":"0000-0001-5686-7103","position":9,"is_corresponding":false},{"id":293941,"name":"Margery A. Connelly","orcid":"0000-0002-3917-592X","position":10,"is_corresponding":false},{"id":484344,"name":"Erwin Garcia","orcid":"0000-0002-2956-2715","position":0,"is_corresponding":true}],"reference_count":57,"raw_metadata":null,"created_at":"2026-07-19T02:05:10.907983Z","pmid":"38338310","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}